Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retifanlimab (INCMGA00012) Plus Chemotherapy in Advanced Solid Tumors
NCT03920839Phase 1Withdrawn
- Sponsor
- Incyte
- Start
- Jul 2019
- Primary completion
- Nov 2019
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of retifanlimab in solid tumor (advanced stage), non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma (MPM), sponsored by Incyte. Primary endpoint: Number of treatment-emergent adverse events. Planned start Jul 2019; status: withdrawn.
02
Drugs
retifanlimab
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)malignant pleural mesothelioma (MPM)
Beyond the preview
Go deeper on NCT03920839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03920839.